Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03654885 · ClinicalTrials.gov registry record · Phase 4
XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 158
- Enrollment target
NCT03654885 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 158 participants.
The verdict
NCT03654885, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 158 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of XEN-45 to trabeculectomy in participants with open angle glaucoma refractory to topical medical therapy.
Interventions
- PROCEDURE Trabeculectomy
- DEVICE XEN-45 Gel Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2021-05-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03654885
The ClinicalTrials.gov registry entry for NCT03654885 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trabeculectomy is the first listed.
NCT03654885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03654885 about?
NCT03654885 is a clinical study titled "XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)". The purpose of this study is to compare the safety and efficacy of XEN-45 to trabeculectomy in participants with open angle glaucoma refractory to topical medical therapy.
What is the current status of trial NCT03654885?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 158 participants. The study started on 2018-10-01. Estimated completion is 2021-05-13.
What interventions are being tested in trial NCT03654885?
The interventions under investigation include: Trabeculectomy (PROCEDURE), XEN-45 Gel Stent (DEVICE).
Who is sponsoring clinical trial NCT03654885?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.